© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Perspective Therapeutics, Inc. (CATX) stock declined over -5.32%, trading at $3.30 on AMEX, down from the previous close of $3.48. The stock opened at $3.46, fluctuating between $3.28 and $3.47 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 19, 2026 | 3.31 | 3.50 | 3.30 | 3.48 | 1.75M |
| Aug 18, 2026 | 3.21 | 3.25 | 3.13 | 3.21 | 757.94K |
| Aug 17, 2026 | 3.21 | 3.31 | 3.19 | 3.22 | 1.17M |
| Aug 14, 2026 | 3.09 | 3.23 | 3.03 | 3.20 | 998.98K |
| Aug 13, 2026 | 3.26 | 3.28 | 3.09 | 3.10 | 1.32M |
| Aug 12, 2026 | 3.18 | 3.28 | 3.11 | 3.26 | 1.19M |
| Aug 11, 2026 | 3.05 | 3.25 | 2.99 | 3.18 | 1.8M |
| Aug 10, 2026 | 3.00 | 3.06 | 2.94 | 3.00 | 913.71K |
| Aug 07, 2026 | 3.03 | 3.06 | 2.94 | 3.00 | 1.05M |
| Aug 06, 2026 | 2.97 | 3.06 | 2.94 | 2.97 | 503.07K |
| Aug 05, 2026 | 3.00 | 3.16 | 2.92 | 2.94 | 1.71M |
| Aug 04, 2026 | 3.01 | 3.12 | 2.98 | 3.00 | 2.29M |
| Aug 03, 2026 | 2.92 | 3.03 | 2.86 | 3.01 | 870.88K |
| Jul 31, 2026 | 3.00 | 3.04 | 2.83 | 2.91 | 827.58K |
| Jul 30, 2026 | 2.89 | 3.00 | 2.87 | 2.99 | 621.72K |
| Jul 29, 2026 | 2.87 | 2.93 | 2.77 | 2.87 | 1.03M |
| Jul 28, 2026 | 2.81 | 2.89 | 2.69 | 2.87 | 999.88K |
| Jul 27, 2026 | 2.95 | 3.02 | 2.82 | 2.82 | 812.02K |
| Jul 24, 2026 | 2.97 | 3.00 | 2.90 | 2.91 | 671.17K |
| Jul 23, 2026 | 2.94 | 2.98 | 2.85 | 2.95 | 582.52K |
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
| Employees | 165 |
| Beta | 1.78 |
| Sales or Revenue | $10.80M |
| 5Y Sales Change% | -0.509% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Medical - Devices |